Publication:
Methyl-beta-cyclodextrin and myriocin alleviate blood-brain barrier impairment in septic rats

dc.contributor.coauthorYilmaz, Canan Ugur
dc.contributor.coauthorOrhan, Nurcan
dc.contributor.coauthorKotil, Tugba
dc.contributor.coauthorArican, Nadir
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAkcan, Uğur
dc.contributor.kuauthorBakbak, Haşim
dc.contributor.kuauthorAyvaz, Ecem
dc.contributor.kuauthorAtış, Müge
dc.contributor.kuauthorAhıshalı, Bülent
dc.contributor.kuauthorKaya, Mehmet
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-12-31T08:22:37Z
dc.date.available2025-12-31
dc.date.issued2025
dc.description.abstractIn this study, the effect of targeting plasma membranes by depleting cholesterol and inhibiting sphingolipid synthesis using methyl-beta-cyclodextrin (M beta CD) and myriocin, respectively, on blood-brain barrier (BBB) integrity was investigated in rats under septic conditions induced by cecal ligation and puncture (CLP). Horseradish peroxidase (HRP) and Evans blue (EB) tracers were used to assess BBB permeability. Caveolin (Cav)-1, claudin-3 and -5, and glucose transporter (Glut)-1 expression was assessed using immunofluorescence staining. In septic rats, M beta CD or myriocin significantly attenuated the increased BBB permeability to both tracers. Upon M beta CD administration, Cav-1 immunoreactivity decreased in the cerebral cortex; however, it increased markedly in the hippocampus in CLP-operated animals. M beta CD and myriocin treatments to septic rats increased claudin-3 immunoreactivity in brain regions, and the difference reached statistical significance with the former treatment. In septic rats, claudin-5 immunoreactivity in brain regions was significantly decreased by M beta CD and increased by myriocin. In CLP-operated animals, M beta CD and myriocin treatments increased Glut-1 immunoreactivity in the brain regions, with the differences reaching statistical significance in the cerebral cortex and hippocampus by the former, while in only the cerebral cortex by the latter treatment. In conclusion, our results suggest that altering lipid profiles of plasma membranes by M beta CD and myriocin can alleviate BBB disruption in septic conditions and, hence, may account for a novel therapeutic modality.
dc.description.fulltextYes
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1007/s00418-025-02421-1
dc.identifier.eissn1432-119X
dc.identifier.embargoNo
dc.identifier.issn0948-6143
dc.identifier.issue1
dc.identifier.pubmed41060462
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-105018279572
dc.identifier.urihttps://doi.org/10.1007/s00418-025-02421-1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/31669
dc.identifier.volume163
dc.identifier.wos001589689600002
dc.keywordsSepsis
dc.keywordsBlood-brain barrier
dc.keywordsMethyl-beta-cyclodextrin
dc.keywordsMyriocin
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofHistochemistry and Cell Biology
dc.relation.openaccessYes
dc.rightsCC BY-NC-ND (Attribution-NonCommercial-NoDerivs)
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCell Biology
dc.subjectMicroscopy
dc.titleMethyl-beta-cyclodextrin and myriocin alleviate blood-brain barrier impairment in septic rats
dc.typeJournal Article
dspace.entity.typePublication
person.familyNameAkcan
person.familyNameBakbak
person.familyNameAyvaz
person.familyNameAtış
person.familyNameAhıshalı
person.familyNameKaya
person.givenNameUğur
person.givenNameHaşim
person.givenNameEcem
person.givenNameMüge
person.givenNameBülent
person.givenNameMehmet
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscovery2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery4c75e0a5-ca7f-4443-bd78-1b473d4f6743

Files